Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions.
While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings.
A number of stocks traded in opposite directions in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare.
Biotech company 10x Genomics (NASDAQ:TXG) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 12.9% year on year to $172.9 million. On the other hand, next quarter’s revenue guidance of $142 million was less impressive, coming in 1.5% below analysts’ estimates. Its non-GAAP profit of $0.48 per share was significantly above analysts’ consensus estimates.
Shares of biotech company 10x Genomics (NASDAQ:TXG)
fell 5.5% in the morning session after the company reported strong second-quarter results that surpassed Wall Street's expectations for both revenue and profitability. The company announced revenue of $172.9 million, a 12.9% increase from the prior year and a significant 24% above analyst estimates. Profitability was a major bright spot, with GAAP earnings per share of $0.28, crushing the consensus forecast of a $0.37 loss per share. This impressive performance overshadowed a slightly cautious outlook for the upcoming third quarter, where the company's revenue guidance of $142 million came in just below analyst projections. Investors focused on the strong current performance, seeing the substantial earnings beat as a positive sign for the company's operational efficiency and market position.
Biotech company 10x Genomics (NASDAQ:TXG) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 12.9% year on year to $172.9 million. On the other hand, next quarter’s revenue guidance of $142 million was less impressive, coming in 1.5% below analysts’ estimates. Its GAAP profit of $0.28 per share was significantly above analysts’ consensus estimates.
10X Genomics (TXG) reported strong Q2 2025 earnings, beating revenue and EPS estimates, sparking a 4.68% after-hours stock surge. Revenue hit $172.91M, up 22.8%, with EPS at $0.28 vs. expected loss. Growth driven by Chromium & Visium platforms.
A number of stocks fell in the afternoon session after industry bellwether UnitedHealth Group (UNH) slashed its 2025 profit forecast after reporting a significant surge in medical costs, sending shockwaves across the health insurance sector.
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around.
Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on.
However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at life sciences tools & services stocks, starting with 10x Genomics (NASDAQ:TXG).
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.5%, S&P 500 +1.0%) as reports pointed to easing tensions between Israel and Iran.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 9.8% year on year to $154.9 million. On the other hand, next quarter’s revenue guidance of $140 million was less impressive, coming in 3.6% below analysts’ estimates. Its non-GAAP loss of $0.10 per share was 64.9% above analysts’ consensus estimates.
Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sale of TSLA, DDD, and ADPT from various funds.
